title: De novo acute megakaryoblastic leukemia with p210 BCR/ABL and t(1;16) translocation but not t(9;22) Ph chromosome.
abstract: Acute megakaryoblastic leukemia (AMKL) is a type of acute myeloid leukemia (AML), in which majority of the blasts are megakaryoblastic. De novo AMKL in adulthood is rare, and carries very poor prognosis. We here report a 45-year-old woman with de novo AMKL with BCR/ABL rearrangement and der(16)t(1;16)(q21;q23) translocation but negative for t(9;22) Ph chromosome. Upon induction chemotherapy consisting of homoharringtonine, cytarabine and daunorubicin, the patient achieved partial hematological remission. The patient was then switched to imatinib plus one cycle of CAG regimen (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor), and achieved complete remission (CR). The disease recurred after 40 days and the patient eventually died of infection. To the best of our knowledge, this is the first report of de novo AMKL with p210 BCR/ABL and der(16)t(1;16)(q21;q23) translocation but not t(9;22) Ph chromosome.
authors.affiliation: Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 1095 Jie-Fang Avenue, Wuhan, Hubei 430030, PR China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Min
authors.forename: Zhang
authors.initials: Z
authors.lastname: Na
authors.forename: Liu
authors.initials: L
authors.lastname: Yanan
authors.forename: Li
authors.initials: L
authors.lastname: Chunrui
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002878:Chromosomes, Human, Pair 1; D002885:Chromosomes, Human, Pair 16; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D007947:Leukemia, Megakaryoblastic, Acute / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D014178:Translocation, Genetic
chemical_list: D016044:Fusion Proteins, bcr-abl
references.citation: Am J Hematol. 2007 Feb;82(2):150-4
references.pmid: 17019692
references.citation: Blood. 2002 Jul 15;100(2):618-26
references.pmid: 12091356
references.citation: Eur J Haematol. 2002 Jul;69(1):58-61
references.pmid: 12270064
references.citation: Leuk Res. 2008 Nov;32(11):1770-5
references.pmid: 18417213
references.citation: Hematol Oncol Stem Cell Ther. 2010;3(1):42-6
references.pmid: 20231813
references.citation: Am J Hematol. 2007 Mar;82(3):231-3
references.pmid: 17022045
references.citation: Ann Intern Med. 1985 Sep;103(3):460-2
references.pmid: 2411180
references.citation: J Pharmacol Exp Ther. 2000 Oct;295(1):139-45
references.pmid: 10991971
references.citation: Blood. 1998 Jul 15;92(2):574-88
references.pmid: 9657758
references.citation: Int J Hematol. 2000 Apr;71(3):238-44
references.pmid: 10846828
references.citation: Cancer Genet Cytogenet. 2004 Jul 1;152(1):52-5
references.pmid: 15193441
references.citation: Haematologica. 1996 Sep-Oct;81(5):423-7
references.pmid: 8952155
references.citation: Leukemia. 2007 Nov;21(11):2376-7
references.pmid: 17554376
references.citation: Blood. 1989 Oct;74(5):1781-90
references.pmid: 2790202
references.citation: Am J Med. 1976 Feb;60(2):209-20
references.pmid: 1062162
references.citation: Cancer Genet Cytogenet. 2009 Sep;193(2):112-5
references.pmid: 19665073
references.citation: Blood. 2002 Oct 1;100(7):2292-302
references.pmid: 12239137
references.citation: Blood. 2000 Oct 1;96(7):2405-11
references.pmid: 11001891
references.citation: Ann Hematol. 2004 Jun;83(6):381-5
references.pmid: 14615910
references.citation: Ann Hematol. 1993 Apr;66(4):171-4
references.pmid: 8485204
references.citation: Cancer. 1990 Feb 15;65(4):940-8
references.pmid: 2297663
references.citation: Blood. 1988 Aug;72(2):402-7
references.pmid: 3165292